Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Post‑viral syndrome is a well‑known medical condition characterized by different levels of
physical, cogni‑tive, and emotional impairment that may persist with fluctuating severity after …

Background The rapid development of COVID-19 vaccines, combined with a high number of
adverse event reports, have led to concerns over possible mechanisms of injury including …

The present use of mRNA vaccines against COVID-19 has shown for the first time the
potential of mRNA vaccines for infectious diseases. Here we will summarize the current …

Several COVID-19 vaccines, some more efficacious than others, are now available and
deployed, including multiple mRNA-and viral vector-based vaccines. With the focus on …

From the beginning of public vaccinations until the relaxation of COVID-19 measures, many
case reports, case series and case–control studies have been published indicating …

COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be
fatal. This systematic review aims to investigate potential causal links between COVID‐19 …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

The optimal booster vaccine schedule against COVID-19 is still being explored. The present
study aimed at assessment of the immunogenicity and antibody persistency of inactivated …